Restoration of the Intestinal Mucosal Barrier in Inflammatory Bowel Disease through Melatonin

Overview

This study investigates the role of melatonin in repairing the intestinal mucosal barrier in inflammatory bowel disease (IBD). Findings indicate that melatonin supplementation can enhance gut microbiota and alleviate colitis through the activation of the SIRT1-LKB1-pAMPK pathway.

Background

Inflammatory bowel disease (IBD) is a chronic condition affecting the gastrointestinal tract, with significant implications for patient quality of life. Sleep disturbances are common in IBD patients, potentially exacerbating disease activity. Understanding the mechanisms by which melatonin can influence gut health is crucial for developing adjunctive therapies.

Data Highlights

IBD patients exhibited lower serum melatonin and fecal 2-oxomelatonin levels. Melatonin supplementation improved intestinal barrier function and reduced colitis severity in mouse models.

Key Findings

• IBD patients have reduced levels of serum melatonin and fecal 2-oxomelatonin.
• Melatonin enhances the secretion of intestinal antimicrobial peptides.
• Melatonin restores the abundance of the probiotic Akkermansia while decreasing the pathogen Desulfovibrio.
• Activation of the SIRT1-LKB1-pAMPK pathway is involved in melatonin's protective effects.
• Inhibition of SIRT1 or pAMPK abolishes the beneficial effects of melatonin in colitis models.

Clinical Implications

Melatonin may serve as a potential adjunctive therapy for IBD by improving gut microbiota and reinforcing the intestinal barrier. Further research is needed to establish its role in clinical practice and to evaluate its efficacy in human populations.

Conclusion

Melatonin shows promise in ameliorating colitis through microbiota modulation and barrier integrity enhancement, warranting further investigation into its therapeutic potential in IBD.

References

1. Journal of Crohn's and Colitis, 2023 -- The Intestinal Mucin Isoform Landscape Reveals Region-Specific Biomarker Panels for Inflammatory Bowel Disease Patient Stratification
2. Journal of Crohn's and Colitis, 2023 -- Disruption of Epithelial Barrier Integrity via Altered GILZ/c-Rel/RACK1 Signaling in Inflammatory Bowel Disease
3. Journal of Crohn's and Colitis, 2023 -- Restoring Prostacyclin/PGI2-PTGIR signaling alleviates intestinal fibrosis in Crohn’s disease via fibroblast-specific YAP/TAZ inhibition
4. Journal of Gastroenterology, 2019 -- Modifying Gut Microbiota to Improve Immune Regulation in the Treatment of Inflammatory Bowel Diseases
5. AGA Living Clinical Practice Guideline on Pharmacological Management of Moderate-to-Severe Ulcerative Colitis - ScienceDirect
6. Association between sleep quality and disease activity in inflammatory bowel disease: A systematic review and meta-analysis - ScienceDirect
7. DOP44 Melatonin Ameliorates Colitis In DSS-fed Mice Via The SIRT1 Pathway | Journal of Crohn's and Colitis | Oxford Academic
8. AGA Living Clinical Practice Guideline on Pharmacological Management of Moderate-to-Severe Ulcerative Colitis - ScienceDirect
9. Association between sleep quality and disease activity in inflammatory bowel disease: A systematic review and meta-analysis - ScienceDirect
10. DOP44 Melatonin Ameliorates Colitis In DSS-fed Mice Via The SIRT1 Pathway | Journal of Crohn's and Colitis | Oxford Academic